CD36 and type 2 diabetes mellitus: We have already reported that teneligliptin significantly reduced ox-LDL uptake, foam cell formation, CD36/ACAT-1 mRNA levels of macrophages derived from T2D patients and db/db mice, an animal model of T2D [14].